GSK PLC
Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight
Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!
Read
Commented by Juliane Zielonka on July 5th, 2024 | 07:35 CEST
Vidac Pharma, BioNTech, GSK: Pioneers in medical progress - Who will win the race?
With around 20 million cancer diagnoses worldwide each year, innovative therapeutic approaches are urgently needed. Companies such as Vidac Pharma are currently developing new ways of treating cancer that could lead to a groundbreaking breakthrough. The reason for this is the discovery of a particular enzyme and its mode of action. At the same time, a patent dispute is raging between Moderna and BioNTech, which could significantly impact the future of mRNA technology. This makes the strategic partnership between GSK and CureVac all the more important. The British company GSK is paying billions of euros for rights to COVID-19 and flu vaccines, which CureVac is to develop. During the pandemic, CureVac was noted more for its shortcomings in vaccine development. Will they achieve a breakthrough now?
Read